ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/Fluorouracil
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/Fluorouracil
25
trial(s) found.
NCT06820463
Advanced
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer (
AndroMETa-CRC
)
Bevacizumab
Fluorouracil
Leucovorin
Oxaliplatin
Panitumumab
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,EGFR-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
fluoropyrimidine
immuno-oncology therapy,EGFR-targeting
immuno-oncology therapy,VEGF-targeting
platinum-based antineoplastic agent
+ Fluorouracil
Colorectal cancer
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06792695
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (
CANTOR
)
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Volrustomig
anti-VEGF monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGF-targeting
therapeutic modality,bispecific antibody
topoisomerase inhibitor
+ Fluorouracil
Colorectal cancer
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06764875
Advanced
Phase 3
Recruiting
A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01) (
D702AC00001
)
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
+ Fluorouracil
Gastroesophageal junction adenocarcinoma
HER2-positive gastric cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06750094
Advanced
Phase 3
Recruiting
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (
OrigAMI-3
)
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
bispecific cMET/EGFR antibody
+ Fluorouracil
Colorectal adenocarcinoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Warringal Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06625775
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study) (
TBBO10203-101
)
PI3K alpha-RAS breaker
+ Fluorouracil
Breast cancer
Colorectal cancer
HER2-negative breast cancer
HER2-positive breast cancer
Non-small cell lung cancer
RAS-mutant colorectal cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06538610
Advanced
NA
Recruiting
Feasibility Study of Ambulatory Holter Monitoring While Receiving Infusional Fluorouracil (5-FU) Chemotherapy (
CTNZ-2022-08
)
fluoropyrimidine
+ Fluorouracil
Gastrointestinal cancer
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
+ Fluorouracil
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06360354
Advanced
Phase 1
Recruiting
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion
PRMT5 inhibitor
+ Fluorouracil
Pancreatic cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06219941
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01) (
D9800C00001
)
anti-CLDN18.2 antibody-drug conjugate
+ Fluorouracil
Biliary tract cancer
Cancer
Gastric cancer
Pancreatic adenocarcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05891171
Advanced
Phase 1
Recruiting
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (
ARC-25
)
anti-CD39 monoclonal antibody
+ Fluorouracil
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Gastric cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Triple-negative breast cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05647122
Advanced
Phase 1
Recruiting
A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors (
EGRET
)
anti EGFR/cMET antibody-drug conjugate
+ Fluorouracil
Head and neck squamous cell carcinoma
Non-small cell lung cancer
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05253651
Advanced
Phase 3
Recruiting
An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer (
MOUNTAINEER-03
)
ERBB2 inhibitor,third generation
anti-EGFR monoclonal antibody
anti-ERBB2 monoclonal antibody
anti-VEGF monoclonal antibody
+ Fluorouracil
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
NCT05067283
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors (
KANDLELIT-001
)
KRAS G12C inhibitor
+ Fluorouracil
Colorectal cancer
NOT Non-small cell lung cancer
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (COMPLETED)
ACTRN12625000583448
Radonc
Phase 2
Not yet recruiting
Total Neoadjuvant Therapy for Organ Preservation in Early-Stage Low Rectal Cancer: The EARLY-TNT Trial (
EARLY-TNT-Trial
)
Capecitabine
Fluorouracil
Leucovorin
Oxaliplatin
Radiotherapy
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
+ Fluorouracil
Rectal adenocarcinoma
ACTRN12624000911594
Advanced
Phase 3
Not yet recruiting
CICAFU
Trial: Randomised, controlled trial of CICAPLAST Baume B5+ versus standard of care on tolerability and observance of topical 5% 5-fluorouracil in Patients diagnosed with Actinic Keratoses (AK)
fluoropyrimidine
+ Fluorouracil
Skin cancer
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12624000005550
Curative
Phase 3
Recruiting
Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicenter prospective randomized, controlled trial (
NeoFOL-R
)
Filgrastim
Fluorouracil
Irinotecan
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
topoisomerase inhibitor
+ Fluorouracil
Pancreatic cancer
ACTRN12623001301651
Curative
Not Applicable
Recruiting
GeneScreen 5-FU: DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Solid Organ Cancer Patients (
GeneScreen-5-FU
)
fluoropyrimidine
+ Fluorouracil
Cancer
ACTRN12623000874617
Advanced
Phase 2
Recruiting
Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression (
Biomarcer-2
)
anti-EGFR monoclonal antibody
topoisomerase inhibitor
+ Fluorouracil
Colorectal cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3844 - Traralgon - Latrobe Regional Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12623000104651
Paed
Phase 1
Recruiting
Phase I Trial of the Safety and Efficacy of Deflexifol for Refractory or Recurrent Paediatric Central Nervous System (CNS) Tumours (
DART
)
Fluorouracil
Central nervous system cancer
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Ependymoma
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12622000180718
Curative
Not yet recruiting
Survival and Patterns of Care in the Era of FLOT-based Chemotherapy for Gastric and Gastroesophageal Adenocarcinoma (
SPACE-FLOT
): An international multicentre cohort study
Docetaxel
Fluorouracil
Leucovorin
Oxaliplatin
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
taxane
+ Fluorouracil
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NZ.9016 - Dunedin - Dunedin Hospital
ACTRN12619001298101
Advanced
Phase 2
Not yet recruiting
A Phase IIa Study to assess the Efficacy and Safety of ASN-002 alone and in combination with chemotherapy in adult participants with Low-Risk Basal Cell Carcinomas (
ASN-002-IL
)
SYK/JAK inhibitor
+ Fluorouracil
Cutaneous basal cell carcinoma
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
ACTRN12617001571369
Radonc
Not yet recruiting
Effect of Stereotactic ablative body radiotherapy for Unresectable Pancreatic cancer with Endoscopic ultrasound inserted fiducial markers and concuRrent chemotherapy on survival rates: SUPER trial.
radiotherapy
+ Fluorouracil
Cancer
Pancreatic cancer
ACTRN12616000554460
Curative
Phase 1
Not yet recruiting
ACES
: Adjuvant Chemotherapy in Early stage oeSophageal cancer- a feasibility study
Cisplatin
Fluorouracil
antimetabolite
cancer therapy
cytotoxic chemotherapy
fluoropyrimidine
platinum-based antineoplastic agent
+ Fluorouracil
Oesophageal cancer
NCT06509906
Advanced
Phase 1
Suspended
An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 in Combination With Topoisomerase 1 Inhibitor-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (
MS202650-0001
)
PARP1-selective inhibitor
+ Fluorouracil
Colorectal adenocarcinoma
NOT Colorectal adenocarcinoma
Solid tumour
NSW
2217 - Kogarah - St George Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ Fluorouracil
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (17)
Not yet recruiting (6)
Suspended (1)
Status unknown (1)
Recruitment Country and State
NSW (16)
VIC (15)
WA (7)
SA (7)
QLD (6)
NZ (2)
ACT (2)
TAS (1)
Phase
Phase 1 (8)
Phase 1 / Phase 2 (1)
Phase 2 (6)
Phase 3 (5)
Trial Type
Advanced (18)
Curative (4)
Radonc (2)
Paed (1)
Cancer Therapy Class
EGFR
28%
VEGF
28%
PD-1/PD-L1
16%
ERBB2
12%
PD-1
12%
MET
8%
CDK4
8%
CDK6
8%
CTLA4
4%
PD-L1
4%
TIGIT
4%
ER
4%
PI3Kalpha
4%
oestrogen axis
4%
Trop2
4%
PRMT5
4%
CLDN18.2
4%
CD39
4%
KRAS
4%
KRAS G12C
4%
JAK
4%
SYK
4%
PARP
4%
PARP1-selective
4%
ALK
4%
ATR
4%
BCR-ABL1
4%
CRAF
4%
FLT3
4%
JAK1
4%
JAK2
4%
KIT
4%
PDGFR
4%
PDGFRA
4%
PI3K
4%
RAF
4%
ROS1
4%
SMO
4%
SRC
4%
VEGFR
4%
YES1
4%
mTOR
4%
mTORC1
4%
mTORC2
4%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (7)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
5011 - Woodville South - The Queen Elizabeth Hospital (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
6150 - Murdoch - Fiona Stanley Hospital (4)
2050 - Camperdown - Chris O'Brien Lifehouse (4)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (3)
3066 - Epping - Northern Hospital (3)
3168 - Clayton - Monash Medical Centre (3)
6009 - Nedlands - One Clinical Research (2)
3002 - East Melbourne - Epworth Freemasons (2)
3021 - St Albans - Western Health - Sunshine Hospital (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
2031 - Randwick - Prince of Wales Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (2)
2605 - Garran - The Canberra Hospital (2)
3011 - Footscray - Footscray Hospital (2)
5112 - Elizabeth Vale - Lyell McEwin Hospital (2)
2109 - North Ryde - Macquarie University Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2139 - Concord - Concord Repatriation General Hospital (1)
3084 - Heidelberg - Warringal Private Hospital (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
2065 - St Leonards - GenesisCare North Shore Private Hospital (1)
2217 - Kogarah - St George Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
2170 - Liverpool - Liverpool Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2200 - Bankstown - Bankstown-Lidcombe Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
5042 - Bedford Park - Flinders Medical Centre (1)
7000 - Hobart - Royal Hobart Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2217 - Kogarah - St George Private Hospital (1)
Cancer Type
Cancer
Solid tumour
Gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Upper gastrointestinal cancer
Thoracic cancer
Gastroesophageal cancer
Pancreatic cancer
Pancreatobiliary cancer
Gastric cancer
Oesophageal cancer
Colorectal adenocarcinoma
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Head and neck cancer
Gastric adenocarcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Breast adenocarcinoma
Breast cancer
Biliary tract cancer
Exocrine pancreatic cancer
Hepatobiliary cancer
Pancreatic adenocarcinoma
Head and neck squamous cell carcinoma
Skin cancer
HER2-positive gastric cancer
HER2-negative breast cancer
HER2-positive breast cancer
RAS-mutant colorectal cancer
Bladder cancer
Cervical cancer
Clear cell renal cell carcinoma
Gynaecological cancer
HPV-related cancer
HPV16-positive cancer
Kidney cancer
Ovarian cancer
Triple-negative breast cancer
Urogenital cancer
Viral-related cancer
Rectal adenocarcinoma
Central nervous system cancer
Diffuse intrinsic pontine glioma
Diffuse midline glioma
Ependymoma
Glioma
H3K27M-mutant glioma
High-grade glioma
Malignant glioma
Neurological cancer
Cutaneous basal cell carcinoma
Non-melanoma skin cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy